Literature DB >> 22251428

Methotrexate: a detailed review on drug delivery and clinical aspects.

Zulfequar Ahamad Khan1, Rahul Tripathi, Brahmeshwar Mishra.   

Abstract

INTRODUCTION: Uses of methotrexate (MTX) are well established for the treatment of various types of malignancy, psoriasis, rheumatological diseases and the medical termination of pregnancy. Formulation and targeting approaches for MTX with controlled release carriers, multiparticulate systems, prodrug and drug conjugates have been found to improve bioavailability, reduce adverse effects and maximize clinical efficacy, compared with conventional methods. AREAS COVERED: This exhaustive literature survey on different electronic databases covers drug delivery and clinical trials on MTX. This review deals with the challenges and achievements of controlled release, multiparticulate, prodrug and drug conjugate systems of MTX. EXPERT OPINION: Therapeutic drug monitoring of MTX is crucial to attain a good efficacy. In spite of the advantages of multiparticulate, prodrug and drug conjugates, clinical applications of such formulations of MTX are still under infancy. These drug delivery systems require the special attention of medical experts for its wider clinical usage, and pharmaceutical experts for its scale-up. The combination of MTX with other antineoplastic and immunosuppressants should also be subjected to clinical trials, such as the combination of misoprostol with MTX in abortion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251428     DOI: 10.1517/17425247.2012.642362

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  41 in total

1.  Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380.

Authors:  Shuhong Wu; Li Wang; Xiao Huang; Mengru Cao; Jing Hu; Hongyu Li; Hui Zhang; Xiaoping Sun; Qing H Meng; Wayne L Hofstetter; Jack A Roth; Stephen G Swisher; Bingliang Fang
Journal:  Bioorg Med Chem       Date:  2014-08-14       Impact factor: 3.641

2.  Beneficial effects of Chrysin against Methotrexate-induced hepatotoxicity via attenuation of oxidative stress and apoptosis.

Authors:  Nemat Ali; Summya Rashid; Sana Nafees; Syed Kazim Hasan; Sarwat Sultana
Journal:  Mol Cell Biochem       Date:  2013-10-24       Impact factor: 3.396

Review 3.  Breast cancer: insights in disease and influence of drug methotrexate.

Authors:  Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal:  RSC Med Chem       Date:  2020-05-28

Review 4.  A comprehensive review on methotrexate containing nanoparticles; an appropriate tool for cancer treatment.

Authors:  Hanifeh Shariatifar; Fateme Ranjbarian; Fahimeh Hajiahmadi; Alireza Farasat
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

5.  Microvesicle-camouflaged biomimetic nanoparticles encapsulating a metal-organic framework for targeted rheumatoid arthritis therapy.

Authors:  Yao Wang; Ming Jia; Xiu Zheng; Chenglong Wang; Yun Zhou; Hong Pan; Yan Liu; Ji Lu; Zhiqiang Mei; Chunhong Li
Journal:  J Nanobiotechnology       Date:  2022-06-03       Impact factor: 9.429

6.  Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism.

Authors:  Fernanda Barbisan; Jéssica de Rosso Motta; Alexis Trott; Verônica Azzolin; Eduardo Bortoluzzi Dornelles; Matheus Marcon; Thaís Doeler Algarve; Marta Maria Medeiros Frescura Duarte; Clarice Pinheiro Mostardeiro; Taís Cristina Unfer; Karen Lilian Schott; Ivana Beatrice Mânica da Cruz
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

7.  The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study.

Authors:  Anna O'Connor; Carter Thorne; Hyeon Kang; Diane Tin; Janet E Pope
Journal:  BMC Musculoskelet Disord       Date:  2016-08-24       Impact factor: 2.362

8.  TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation.

Authors:  Valentino Laquintana; Nunzio Denora; Annalisa Cutrignelli; Mara Perrone; Rosa Maria Iacobazzi; Cosimo Annese; Antonio Lopalco; Angela Assunta Lopedota; Massimo Franco
Journal:  Int J Mol Sci       Date:  2016-06-18       Impact factor: 5.923

9.  Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models.

Authors:  Tatsuya Tamura; Yoshinobu Higuchi; Hidetomo Kitamura; Naoaki Murao; Ryoichi Saitoh; Tadashi Morikawa; Haruhiko Sato
Journal:  Arthritis Res Ther       Date:  2016-04-01       Impact factor: 5.156

10.  A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer.

Authors:  Shengsheng Zhu; Qinxia Wang; Juan Jiang; Yongwei Luo; Zuyue Sun
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.